Pfizer’s chief scientific officer and president of R&D, Mikael Dolsten, has said he will step down from the role in the coming months, kicking off the search for a successor. Dolsten’s ...

A combination shot including vaccines for both sicknesses failed to measure up in a Phase 3 trial, Pfizer said.

Pfizer faced a setback with its combo Covid-flu shot, which could allow Moderna and others to gain ground. Meanwhile, Epic’s ...

Five years ago — before the pandemic — Pfizer’s head of research and development, Mikael Dolsten, told STAT he kept a chess set in his office that he got as a gift from a former CEO of the ...

Pfizer on Tuesday said Mikael Dolsten, chief scientific officer and president, Pfizer Research & Development, is leaving after more than 15 years with the drugmaker. Pfizer said it is launching ...

US pharmaceutical giant Pfizer on Tuesday said its chief scientific officer Mikael Dolsten, a key figure behind the ...

Yes! I want to get the latest chemistry news from C&EN in my inbox every week. ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly ...

Pfizer on Tuesday Csaid hief Scientific Officer Mikael Dolsten, a key figure behind the development of its COVID-19 vaccine, will resign, after a more than 15-year career at the drugmaker.

Pfizer’s top scientist Mikael Dolsten is stepping down after leading the drugmaker’s research and development for the past 15 years, a period that includes Pfizer’s remarkable success ...

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced that the company is launching the process to identify a successor for Dr. Mikael Dolsten, Pfizer’s Chief Scientific Officer ...

Mikael Dolsten, Pfizer's outgoing chief scientific officer, said at a conference in March that the company hopes to launch its combination shot in 2025. It's unclear whether Friday's results ...